Formulation of Amphotericin B in PEGylated Liposomes for Improved Treatment of Cutaneous Leishmaniasis by Parenteral and Oral Routes

Formulation of Amphotericin B in PEGylated Liposomes for Improved Treatment of Cutaneous Leishmaniasis by Parenteral and Oral Routes

Liposomal amphotericin B (AmB) or AmBisome<sup>®</sup> is the most effective and safe therapeutic agent for visceral leishmaniasis (VL), but its clinical efficacy is limited in cutaneous leishmaniasis (CL) and HIV/VL co-infection. The aim of this work was to develop a formulation of AmB...

Full description

Bibliographic Details
Main Authors: Guilherme S. Ramos, Virgínia M. R. Vallejos, Gabriel S. M. Borges, Raquel M. Almeida, Izabela M. Alves, Marta M. G. Aguiar, Christian Fernandes, Pedro P. G. Guimarães, Ricardo T. Fujiwara, Philippe M. Loiseau, Lucas A. M. Ferreira, Frédéric Frézard
Format: Article
Language:English
Published: MDPI AG 2022-05-01
Series:Pharmaceutics
Subjects:
liposomes
amphotericin B
leishmaniasis
oral route
PEGylation
cutaneous leishmaniasis
Online Access:https://www.mdpi.com/1999-4923/14/5/989

Similar Items

Similar Items